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Abstract: Introduction: In the scenario of vitamin D deficiency, this incident is prevalent and with risks to public 
health in the world, reaching approximately 90% of individuals. Hypovitaminosis D can cause, mainly in the elderly, 
lower bone mineral density, fractures, muscle weakness, falls, and acute respiratory infection. Objective: To 
evaluate the main clinical results on vitamin D levels in the elderly, as well as to analyze which daily or weekly dose 
of vitamin D is most effective in the elderly in reducing the number of falls and fractures. Methods: The present 
study developed a systematic review, addressing randomized clinical studies, diverse clinical studies, systematic 
reviews, meta-analysis, and the latest international consensus, following the rules of PRISMA. Results and 
Conclusion: A total of 152 articles were found involving the dosage and the impact of vitamin D in the elderly. In 
total, 72 articles were evaluated in full and 30 were included. According to the main literary findings, vitamin D 
deficiency implies problems with mineralization and bone mineral density, causing fractures and an increase in the 
number of elderly falls. In this sense, SBEM recommends maintaining vitamin D concentrations above 30 ng/mL. 
Also, vitamin D deficiency points to the occurrence of neurological diseases such as cognitive decline, risk of 
Alzheimer's disease, and depression. In the current scenario of the pandemic, vitamin D points as an important 
modulator of the immune system, and its deficiency promotes the unregulated release of cytokines, leading to 
complications in patients with COVID-19. 
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1. Introduction 
 In the scenario of vitamin D deficiency, this 
incident is prevalent and with risks to public health in 
the world, reaching approximately 90% of individuals 
[1]. Vitamin D deficiency can be understood in the 
measurement of serum 25-hydroxyvitamin D (25 (OH) 
D) <50 nmol/L or 20 ng/mL) [1,2], with severe 
deficiency (25 (OH) D <30 nmol/ L or 12 ng/mL) is 
found in more than 10% of Europeans [3]. 
In this regard, hypovitaminosis D can cause, 
especially in the elderly, fractures and lower bone 
mineral density [4,5], falls and acute respiratory 
infection and muscle weakness [6,7]. In this context, 
eating foods rich in vitamin D can improve the vitamin 
D status of the entire population [8]. In addition, genetic 
studies can help to define individual vulnerability due to 
vitamin D deficiency [9,10]. In cases of vitamin D 
deficiency, secondary hyperparathyroidism and 
increased bone resorption can occur [11]. The vitamin 
D values for PTH normalization are between 28 and 40 
ng/mL [11]. In this sense, it is necessary the action 
active vitamin D in the duodenum for calcium absorption 
[7]. Thus, it is necessary to correctly establish both the 
identification and treatment of hypovitaminosis D.  
In this sense, the Department of Bone 
Metabolism of the Brazilian Society of Endocrinology and 
Metabology (SBEM) seeks scientific efforts for the 
diagnosis and adequate treatment of this population. 
Therefore, the present study aimed to evaluate the main 
clinical results on vitamin D dosage levels in the elderly, 
as well as to analyze which daily or weekly vitamin D 
dose is most effective in the treatment of 
osteopenia/osteoporosis, immunity, weakness muscle in 
the elderly and reducing the number of falls and 
fractures in the elderly. 
 
2. Methods 
2.1. Study Design 
The present study developed a systematic 
review (rules of PRISMA. Available at: 
HTTP://www.prisma-statement.org/ [12]), addressing 
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randomized clinical studies, diverse clinical studies, 
systematic reviews, meta-analysis, and consensus.  
2.2. Data sources and research strategy 
The descriptors used were elderly, vitamin D, 
25(OH)D, hypovitaminosis, immunity, and inflammatory 
process, with publications from 2000 to 2021. SCOPUS, 
Cochrane Library, PubMed, Science Direct, and Google 
Scholar databases were used. 
 
2.2. Study quality and risk of bias 
For the analysis of the quality of the studies, the 
GRADE instrument [13] was used, based on the strata 
of levels of scientific evidence, according to the nature 
of each study. For the risk of bias, the Cochrane 
instrument was used [14]. 
 
3. Results and Discussion 
A total of 152 articles were found involving the 
dosage and the impact of vitamin D in the elderly. In 
total, 72 articles were evaluated in full and 30 were 
included and evaluated in the present study to compose 
the systematic review (Figure 1). The overall 
assessment resulted in 5 studies with a high risk of bias 
and 3 studies with uncertain risk. The highest risk of 
bias were related to the number of participants in each 
study addressed, and the uncertain risk was related to 
the use of vitamin D in overdosage.  
After a thorough analysis of these selected 
studies, it was found that in the elderly population, there 
is scientific evidence of the benefits of vitamin D on the 
risk of fractures. According to meta-analysis and 
guidelines, the recommended vitamin D doses are those 
capable of maintaining the patient to plasma 25 (OH) D 
values above 30 ng/mL, thus avoiding secondary 
hyperparathyroidism and the increase in bone 
resorption [15-17].  
Figure 1. Eligibility of the studies. 
In this sense, it is recommended to keep 
vitamin D concentrations above 30 ng/mL to prevent 
secondary hyperparathyroidism, requiring daily doses 
between 1,000 and 2,000 IU [18]. A relationship 
between low vitamin D levels and falls and fractures has 
been described [19]. As a corollary of this, a meta-
analysis study showed a decrease in fracture prevention 
with the use of calcitriol, similar to that obtained with 
doses above 700 IU of vitamin D3 per day [20]. 
In this context, eldecalcitol has a strong 
inhibitory effect on bone resorption and increases bone 
mineral density, showing a 26% reduction in the 
incidence of new vertebral fractures in three years and 
71% in the risk of wrist fracture compared to alfacalcidol 
[21-25]. In addition, a meta-analysis examined the 
effect of vitamin D3 supplementation. Thus, 47 
randomized controlled trials with 58,424 participants 
were evaluated. The main populations were elderly 
women under the age of 80 years. Vitamin D3 
supplementation showed a significant effect in reducing 
falls. However, vitamin D3 supplementation decreased 
the incidence of falls, but only in the presence of calcium 
supplementation. Furthermore, vitamin D together with 
calcium supplementation can significantly reduce 
fracture rates [26]. 
Also, a cross-sectional study recruited 60 
patients (mean age 65 years) and looked at vitamin D 
deficiency and hip fractures. Approximately 10% had 
vitamin D deficiency and another 53.33% had vitamin D 
insufficiency. In addition, hip fracture patients had lower 
serum vitamin D3 levels compared to those patients 
without osteoporosis [27]. 
 
3.1 Cognitive Function in the Elderly 
The central nervous system has several vitamin 
D receptors in several areas. In this regard, studies have 
shown that low vitamin D intake is associated with 
cognitive decline, with greater chances of developing 
Alzheimer's disease and depression. This is due to the 
formation and aggregation of β-amyloid, dysregulation 
of the GABAergic system, and increased calcium influx 
in neurons [28]. Thus, vitamin D plays an important role 
in pathophysiological pathways that occur with aging 
[29,30]. 
 
3.2 Vitamin D and Immune Function in the 
Elderly 
In the current pandemic scenario for COVID-19, 
in genomic terms, SARS-CoV-2 targets in human cells 
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identified that vitamin D is among the three molecules 
with the highest mitigation score for this infection, ie, 
vitamin D supplementation may improve the prognosis 
of COVID-19 [18]. 
In this context, a study of 260 participants aged 
≥ 65 years with COVID-19 compared the effect of a 
single high oral dose of cholecalciferol versus a single 
standard oral dose on the mortality rate in elderly 
patients with COVID-19. Participants were randomized 
to high-dose cholecalciferol (2 vials of 200,000 IU) or 
standard-dose cholecalciferol (vials of 50,000 IU). The 
results showed that high-dose vitamin D 
supplementation can be an effective, well-tolerated, 
easily, and immediately accessible treatment for COVID-
19 [30]. 
Besides, one study hypothesized that vitamin D 
deficiency (<20 ng/mL) could increase the risk of 
developing severe COVID-19 infection. Eighty patients 
were included, of which 31 (39%) had the outcome. 
Vitamin D deficiency pointed to an increased risk of 
developing severe COVID-19 for age, sex, obesity, heart 
disease, and kidney disease [31]. 
In addition, there is evidence of a relationship 
between vitamin D deficiency and unregulated cytokine 
release in COVID-19. Mean vitamin D levels in older 
adults suggest a role for vitamin D in reducing the 
mortality rate [18]. Thus, a recently published 
prospective cohort study in the United Kingdom 
assessed the importance of vitamin D deficiency in 
elderly patients with COVID-19. Findings showed that 
patients with lower vitamin D concentrations (≤30 
nmol/L) at the time of acute infection had a greater 
release of cytokines and were more likely to become 
hypoxic and on ventilatory support [32]. In this context, 
therefore, vitamin D deficiency and the worst 
hospitalization outcomes of patients infected with 
COVID-19 are shown to be closely related [32]. 
Therefore, it is established that there is an 
interaction between vitamin D and various components 
of the innate and adaptive immune responses to 
infections. In addition to its anti-inflammatory 
properties, vitamin D has a protective effect on alveolar 
epithelial cells, preserving endothelial integrity and 
reducing vascular permeability. Despite this, vitamin D 
can induce ACE-2 expression. However, while the 
increase in ACE-2 expression was initially predicted to 
amplify the risk of infection and severity, ACE-2 has also 
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recommends maintaining vitamin D concentrations 
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